The need to manage the risk of thromboembolism in COVID-19 patients.

Link to article at PubMed

Related Articles

The need to manage the risk of thromboembolism in COVID-19 patients.

J Vasc Surg. 2020 May 14;:

Authors: Khan IH, Savarimuthu S, Tsun Leung MS, Harky A

Abstract
COVID-19 first presented in Wuhan, Hubei Province, China, in December 2019. Thought to be of zoonotic origin, it has been named SARS-CoV-2 (COVID-19) and has spread rapidly. As of April 20th, 2020, there have been more than 2.4 million cases recorded worldwide. The inflammatory process, cytokine storm, and lung injury that are associated with COVID-19 can put patients at an increased risk of thrombosis. It is uncertain what the total incidences of thrombotic events in COVID-19 patients is currently at. Those with more severe disease and with other risk factors, including increasing age, male sex, obesity, cancer, comorbidities, and intensive care unit admission, are at higher risk of these events. However, there is little international guidance on managing these risks in COVID-19 patients. In this paper, we explore the current evidence and theories surrounding thrombosis in these unique patients and reflect on experience from our center.

PMID: 32417304 [PubMed - as supplied by publisher]

Leave a Reply

Your email address will not be published.